17:53 , Nov 9, 2018 |  BC Week In Review  |  Company News

J&J adds to lung cancer arsenal with Yuhan deal

Janssen Pharmaceuticals Inc. licensed non-small cell lung cancer (NSCLC) compound lazertinib from Yuhan Corp. (KSE:000100) for $50 million up front and up to $1.2 billion in development and commercial milestones, giving Johnson & Johnson (NYSE:JNJ)...
00:15 , Nov 6, 2018 |  BC Extra  |  Company News

J&J adds to lung cancer arsenal with Yuhan deal

Janssen Pharmaceuticals Inc. licensed non-small cell lung cancer (NSCLC) compound lazertinib from Yuhan Corp. (KSE:000100) for $50 million up front and up to $1.2 billion in development and commercial milestones, giving Johnson & Johnson (NYSE:JNJ)...
15:43 , Sep 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Patient sample, cell culture and mouse studies suggest antagonizing AHR could help treat MM. In patients, high tumor levels of AHR correlated with poor survival. In multiple Velcade bortezomib-resistant and -sensitive...
23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018...
21:37 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture studies suggest promoting interactions between miR-34a and tRNA-iMet could help treat breast cancer. In a panel of human breast cancer cell lines, levels of miR-34a were lower and levels of...
19:52 , Jun 28, 2018 |  BC Innovations  |  Emerging Company Profile

Stress relief for neurons

Aquinnah Pharmaceuticals is developing disease-modifying therapies for amyotrophic lateral sclerosis and Alzheimer’s disease by inhibiting the formation of stress granules that promote protein aggregation in neurons. Stress granules are protein-RNA complexes assembled by RNA-binding proteins...
00:15 , Jun 23, 2018 |  BioCentury  |  Regulation

Emergency preparedness

Borrowing a page from the software industry, FDA Commissioner Scott Gottlieb believes that licensing rather than selling certain antibiotics could help address the crisis of multidrug resistant pathogens. He is hoping to work with CMS...
15:28 , Jun 8, 2018 |  BC Week In Review  |  Company News

J&J, Boston U partner to map early detection biomarkers for lung cancer

The Johnson & Johnson Innovation LLC unit of Johnson & Johnson (NYSE:JNJ) and Boston University unveiled a five-year collaboration to identify biomarkers for early stage lung cancer. The research includes a precancer genome atlas (PCGA)...
22:49 , Jun 6, 2018 |  BC Extra  |  Company News

J&J, Boston U partner to map early detection biomarkers for lung cancer

The Johnson & Johnson Innovation LLC unit of Johnson & Johnson (NYSE:JNJ) and Boston University unveiled a five-year collaboration to identify biomarkers for early stage lung cancer. The research includes a precancer genome atlas (PCGA)...
16:31 , May 4, 2018 |  BioCentury  |  Emerging Company Profile

Needling out Alzheimer’s

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding...